Keynote at Wonderland: Miami

TORONTO, Ontario Nov. 8, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is delighted to announce that its CEO, Dr. Roger McIntyre, has been selected to be a keynote speaker at the Wonderland: Miami conference.

The two-day event, which is scheduled to begin Mon., Nov. 8 at the Adrienne Arsht Center for the Performing Arts of Miami-Dade County, will act as a launching pad for innovative companies connected to the psychedelic medicine space.

Dr. McIntyre will discuss the challenges patients with medication-resistant mental health issues face in accessing ketamine and other psychedelic therapies as well as developing new therapies. He will also outline best practices for clinicians according to the international guidelines developed by him and other members of Braxia Scientific’s leadership, as published in the American Journal of Psychiatry. This presentation will take place Mon., Nov. 8, at 1 p.m. ET.

As a world-leading depression researcher, Dr. McIntyre has been named one of the world’s most influential scientific minds by Clarivate for seven consecutive years. He is a professor of Psychiatry and Pharmacology at the University of Toronto and holds professorships at universities in the United States and Asia, including the University of California Riverside School of Medicine, State University of New York (SUNY), Upstate Medical University in Syracuse, N.Y., Guangzhou Medical University, and the College of Medicine at Korea University. He is also the founder of the Canadian Rapid Treatment Center of Excellence, a wholly owned Braxia subsidiary that operates a network of ketamine clinics treating depression and other mental health disorders.

Braxia Scientific will also participate in a panel discussion on Tues., Nov. 9, at 2:30 p.m ET, entitled “Ketamine Treatment Goes Mainstream,” in which Dr. McIntyre will join fellow VIPs Lamar Odom and Zappy Zapolin to talk about the rising awareness of ketamine as a transformative treatment for depression, anxiety, post-traumatic stress disorder (PTSD), addiction and other mental health disorders.

Lamar Odom is a two-time National Basketball Association champion, Olympic gold medalist, New York Times bestselling author, and mental health advocate. Odom has spoken openly about the profound healing he experienced with psychedelic medicine and his journey is featured in Lamar Odom Reborn, a documentary film showcasing his recovery following a very public overdose and near-death experience in 2015. Reborn documents Odom’s journey to break patterns of addiction through medically guided alternative treatments for depression and drug dependency, including meditation, the plant medicine ibogaine, and the administration of medical ketamine.

Zappy Zapolin is the co-founder and executive chairman of KetaMD, a developing telemedicine platform that provides at-home medical ketamine treatments. He is also an award-winning filmmaker dedicated to the expansion of human consciousness and has been described as the “psychedelic concierge to the stars” for helping celebrities and business icons achieve a conscious transformation.

For additional information on Wonderland: Miami, please visit https://microdose.buzz/wonderland/miami.

For those who are unable to attend the conference in person, a virtual pass is available for purchase, and includes access to the event’s livestream and session recordings, as well as select other perks.

About Braxia Scientific Corp.

Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders. Through its medical solutions, Braxia aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others. Braxia is primarily focused on (i) owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and (ii) research activities related to discovering and commercializing novel drugs and delivery methods. Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform. Through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., Braxia currently operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga, Toronto, Ottawa, and Montreal.

FOR FURTHER INFORMATION PLEASE CONTACT:
Braxia Scientific Corp.
Tel: 416-762-2138
Email: [email protected]
Website: www.braxiascientific.com

The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

Forward-looking Information Cautionary Statement

This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance are “forward-looking statements.”

Forward-looking statements include statements about the intended promise of ketamine-based treatments for depression and the potential for ketamine to treat other emerging psychiatric disorders, such as Bipolar Depression. Such forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events, or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties include, among others, the failure of ketamine, psilocybin and other psychedelics to provide the expected health benefits and unanticipated side effects, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and engaging in activities that could be later determined to be illegal under domestic or international laws. Ketamine and psilocybin are currently Schedule I and Schedule III controlled substances, respectively, under the Controlled Drugs and Substances Act, S.C. 1996, c. 19 (the “CDSA”) and it is a criminal offence to possess such substances under the CDSA without a prescription or a legal exemption. Health Canada has not approved psilocybin as a drug for any indication, however ketamine is a legally permissible medication for the treatment of certain psychological conditions. It is illegal to possess such substances in Canada without a prescription.

These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements.

Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, including the Amended and Restated Listing Statement dated April 15, 2021, which are available at www.sedar.com. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements.